MONTRELIEF FX Tablet is a fixed-dose combination medication composed of Montelukast Sodium 10 mg and Fexofenadine Hydrochloride 120 mg, both of which act through complementary mechanisms to relieve symptoms of allergic rhinitis and related conditions. Montelukast is a leukotriene receptor antagonist that works by blocking leukotriene D4 at the cysteinyl leukotriene receptor, reducing inflammation, nasal congestion, and bronchoconstriction. Fexofenadine is a non-sedating second-generation antihistamine that selectively blocks peripheral H1 receptors to control sneezing, itching, rhinorrhea, and watery eyes.

This combination is particularly effective for patients who suffer from both upper and lower airway allergic symptoms, such as in cases of seasonal or perennial allergic rhinitis, chronic idiopathic urticaria, and exercise-induced bronchospasm. The non-drowsy formula allows patients to maintain normal activity and focus throughout the day while achieving full symptomatic relief.

Manufactured by Bluepill Express in WHO-GMP certified facilities, MONTRELIEF FX is produced using state-of-the-art equipment and stringent quality control measures to ensure purity, potency, and safety. The production process involves multi-tier testing of raw materials, in-process control, finished product analysis, and long-term stability evaluation. The tablets are film-coated, easy to swallow, and designed for once-daily oral administration.

MONTRELIEF FX offers consistent pharmacokinetics, quick onset of action, and prolonged duration of effect, making it suitable for both acute and long-term allergy management. It does not cause sedation or impair cognitive functions, distinguishing it from older antihistamines. Fexofenadine's minimal blood-brain barrier penetration reduces the risk of central nervous system side effects, while Montelukast’s anti-inflammatory action helps improve overall respiratory health.

Each batch of MONTRELIEF FX Tablet is supported by a complete regulatory dossier, including Certificate of Analysis (COA), stability data, bioequivalence profiles (where applicable), and packaging customization to meet country-specific labeling requirements. The tablets are available in blister or alu-alu packaging for global export, catering to clients across Asia, Africa, CIS countries, the Middle East, and Latin America.

Bluepill Express maintains high compliance with global pharmaceutical regulations and facilitates smooth registration, importation, and marketing support for our international clients. As a trusted name in third-party manufacturing and private labeling, we offer scalable solutions for pharma distributors, marketing companies, hospitals, and institutions.

MONTRELIEF FX is a preferred therapeutic option for patients seeking fast, reliable, and side-effect-free allergy relief. With its dual-action mechanism and favorable safety profile, it enhances quality of life and improves patient adherence. Bluepill Express is proud to manufacture this combination as part of its expanding portfolio of allergy and respiratory care solutions, making quality affordable medicine accessible worldwide.